Sharechat Logo

Genesis income surges

By Phil Boeyen, ShareChat Business News Editor

Wednesday 31st January 2001

Text too small?
Upfront licensing revenue for its psoriasis treatment has helped recently listed biotech company Genesis Research (NZSE: GEN) turn a forecast $9.97 million loss into a $723,000 profit.

Genesis says total operating income for the year to the end of December almost quadrupled to $28.66 million from $7.19 million the previous year.

The income boost was from sublicensing the company's PVAC treatment for psoriasis to companies in Japan and North America. Its US partner Corixa is also looking to license the treatment in Europe and the rest of the world, promising even further returns.

Bottom-line profit of $723,000 compares with a loss of $7.15 million in 1999 and a forecast loss in the company's prospectus of $9.97 million.

The company says the increased revenue, together with its successful capital raising programme, enabled it to increase expenditure on research and development to $18.9 million, up 58% from $11.9 million in 1999.

Funds were applied to research into new therapeutics and other potential products as well as the Phase II Clinical trials for the PVAC psoriasis treatment currently underway in USA, Brazil and Philippines.

Results of the USA trial are due to be announced early in February.

"As this result shows, the prime beneficiary of Genesis' revenue growth and capital raising is our enhanced research programme," says the company's founder and CEO Dr James Watson.

"To operate from this solid base gives us an immense advantage in what is a highly competitive environment."

Genesis says staff numbers rose during the year from 83 to 124 through an active national and international recruitment programme.

The company finished the year with cash reserves of $61.93 million. No dividend is being paid.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Genesis Research directors quit due to lack of funds & communication
Genesis Research has ‘lack of funds’, seeks legal advice on future
Genesis Research halted from trading pending statement
Genesis Research calls off proposed merger with Mariposa Health
Kupe earnings bolster Genesis 1H profit by 125%
Genesis Research plans "reverse takeover"
Genesis Research director Graham Chin resigns in wake of rift with UBNZ
Tekapo purchase knocks $73m off Genesis bottom line
UBNZ gets in deeper with Genesis Research
Genesis Energy beats forecast